Glenview State Bank Trust DEPT. continued to hold its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,050 shares of the pharmaceutical company’s stock at the end of the second quarter. Glenview State Bank Trust DEPT.’s holdings in GlaxoSmithKline PLC were worth $347,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the stock. FMR LLC boosted its stake in shares of GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans boosted its stake in shares of GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after buying an additional 1,371,490 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares during the last quarter. 8.96% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.26% on Friday, hitting $42.66. 2,280,071 shares of the stock were exchanged. The company has a 50-day moving average of $43.28 and a 200 day moving average of $41.70. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $45.58. The firm has a market cap of $104.22 billion, a P/E ratio of 47.72 and a beta of 1.04.
GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.62. The company had revenue of $9.23 billion for the quarter, compared to the consensus estimate of $9.09 billion. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. Equities research analysts expect that GlaxoSmithKline PLC will post $2.86 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, July 13th. Shareholders of record on Friday, May 12th were issued a $0.483 dividend. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.93 dividend on an annualized basis and a yield of 4.53%. The ex-dividend date was Wednesday, May 10th. GlaxoSmithKline PLC’s payout ratio is currently 233.74%.
ILLEGAL ACTIVITY WARNING: “Glenview State Bank Trust DEPT. Has $347,000 Position in GlaxoSmithKline PLC (GSK)” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/07/22/glenview-state-bank-trust-dept-has-347000-position-in-glaxosmithkline-plc-gsk.html.
GSK has been the topic of a number of analyst reports. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a report on Monday, April 17th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, April 25th. TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and lowered their target price for the company from $45.58 to $37.20 in a report on Wednesday, April 5th. Finally, Exane BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a report on Wednesday, April 5th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $46.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.